ABSTRACT Using an antiserum to a 15-amino acid synthetic peptide corresponding to amino acids 63-77 of rat preprosomatostatin (rat somatostatin cryptic peptide, RSCP), we have compared the distribution of immunoreactive RSCP (IR-RSCP) with that of immunoreactive somatostatin-14 in the rat brain. IR-RSCP was present in neuronal cell bodies, processes, and axon terminals in the hypothalamic tuberoinfundibular system as well as in diverse regions of the central nervous system in an identical distribution to immunoreactive somatostatin. These observations indicate that in neurons the somatostatin prohormone or the NH2-terminal extension peptide of somatostatin-28 (or both) is stored and transported intracellularly along with somatostatin 14. In addition, the presence of IR-RSCP in nerve terminals suggests that this material may be secreted as a hormone or neuromodulator and may serve as a biologic marker of somatostatin secretion.
The tetradecapeptide somatostatin is an important hypophysiotropic hormone, influencing the release of growth hormone and thyroid-stimulating hormone from the anterior pituitary gland (1, 2) . Somatostatin has also been found in the gastrointestinal tract and pancreatic islets, where it regulates the secretion of gastrin, insulin, cholecystokinin, vasoactive intestinal peptide, and glucagon (3, 4) . In addition, the tetradecapeptide is widespread within the central and peripheral ner- vous system, where it serves as a neurotransmitter or neuromodulator (5-7).
Several higher molecular weight immunoreactive forms of somatostatin have been found in extracts of brain and peripheral tissues (8) (9) (10) (11) (12) (13) (14) . One of these molecules, an amino-terminally extended form of somatostatin consisting of 28 amino acids (SS-28), appears to be at least as potent as SS-14 in inhibiting growth hormone, insulin, and glucagon secretion (15, 16) . Pulse and pulse-chase labeling studies in brain and pancreatic islets indicate that, similar to SS-14, SS-28 is derived from a precursor consisting of itself linked to a large NH2-terminal-extension peptide (17, 18) .
Recently, Goodman et al. (19) reported the nucleotide sequence of a cDNA encoding SS-28 derived from a rat medullary thyroid carcinoma. From the nucleotide sequence of the cDNA, the corresponding amino acid sequence of rat SS-28 was derived and the amino acid sequence of much of the remainder of the rat prosomatostatin molecule was deduced. The complete nucleotide sequence of rat preprosomatostatin has since been determined ( Fig. 1) (20) . This molecule is composed of a leader sequence of 24 amino acids at the amino terminus followed by a pro-region of 64 amino acids and the SS-28 sequence at the carboxyl terminus.
Under cell-free conditions, the leader sequence is enzymatically removed, resulting in the formation of a prosomatostatin molecule of 92 amino acids (20) . In intact cells, prosomatostatin is presumably further cleaved to produce the biologically active SS-14 and SS-28 molecules and an NH2-terminal extension peptide of 64 amino acids. The distribution, biologic fate, and activity of the NH2-terminal extension peptide have yet to be established.
To determine the neuroanatomical distribution and fate of the somatostatin prohormone, we have prepared antiserum to the 15-amino acid peptide Thr-Glu-Asn-Asp-Ala-Leu-Glu-ProGlu-Asp-Leu-Pro-Gln-Ala-Ala corresponding to amino acids 63-77 of rat preprosomatostatin (Fig. 1 
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port. The t-butyloxycarbonyl group was used to protect the aamino group of each amino acid during coupling. The carboxylic side groups of aspartic and glutamic acids were protected as benzyl esters; the threonine hydroxyl group was protected as the O-benzyl ether. All amino acids were obtained from Bachem Fine Chemicals (Torrance, CA). Purification was by gel filtration (Bio-Gel P4) chromatography as described (23) . The structure of the purified peptide was confirmed by amino acid composition and Edman sequence analysis (24) .
Antiserum Preparation and Characterization. Antibody to synthetic cyclic SS-14 (Bachem Fine Chemicals) was prepared by mixing 2 mg of the synthetic tetrapeptide with 1 mg of methylated bovine serum albumin. Immunization was carried out with a total of 1,500 Ag of SS-14 emulsified in 2 ml of complete Freund's adjuvant and administered by multiple intradermal injections. The serum derived from a single animal (no. 669) was found to have a sensitivity of 15 pg per tube at a titer of 1:28,000 in the radioimmunoassay and did not crossreact with synthetic thyrotropin-releasing hormone, luteinizing hormonereleasing hormone, vasopressin, oxytocin, angiotensins I and II, cholecystokinin, or anterior pituitary hormones. The specificity of the antiserum for immunohistochemistry was shown by the complete absence of staining when antiserum previously adsorbed (titer, 1:1,000) with 1 AM synthetic SS-14 was used.
By using alanine-substituted analogues of SS-14 (positions 2, 4, and 6-13) (a gift of J. Rivier, Salk Institute, La Jolla, CA) for the adsorption studies, the antiserum was shown to be COOHterminally directed, requiring the presence of the native sequence amino acids at positions 9 and 11-13 for recognition.
Antibody to RSCP was prepared by mixing 1 mg of synthetic peptide with 1 mg of methylated bovine serum albumin. Immunization was carried out with 50 pg of RSCP emulsified in 1 ml complete Freund's adjuvant and administered by multiple intradermal injections. The serum derived from one rabbit (VG2) had a sensitivity of 25 pg per tube in a radioimmunoassay at a titer of 1:6,000 and did not crossreact with SS-14 or SS-28. Antiserum to RSCP specifically immunoprecipitated both preprosomatostatin and prosomatostatin synthesized in cell-free translations of mRNA isolated from a rat medullary thyroid carcinoma (unpublished data).
Immunohistochemical Procedure. The unlabeled peroxidase-antiperoxidase technique (25) , as modified for free-floating thick tissue sections, was used. The tissues were treated sequentially with (i) Tris/NaCI/0.2% Triton X-100 (Sigma) for 30 min at 4°C to improve antibody penetration, (ii) Tris/NaCl/ 1% hydrogen peroxide for 20 min at 4°C to diminish endogenous peroxidase, and (iii) Tris/NaCl/0.075% gelatin for 5 min at room temperature to diminish nonspecific binding by the antibodies. Then, serial tissue sections were immersed in either a 1:500-1:1,000 dilution of antiserum to the cryptic peptide or a 1:1,000-1:2,000 dilution of antiserum to SS-14. Antisera dilutions were made in Tris/NaCl/0.3% Triton X-100/25 mM RESULTS The immunoreaction product for RSCP was present in cell bodies, axons, and axon terminals in all regions of the brain in which IR-SS could be found. This was particularly striking in the hypothalamic tuberoinfundibular system. Here, cell bodies of the periventricular nucleus staining for IR-RSCP ( Fig. 2A) and IR-SS (Fig. 2B) were numerous, extending into the parvocellular subdivision of the paraventricular nucleus. Although well visualized in the untreated animal, these cells were seen to best advantage after administration of colchicine, due to a substantial increase in immunoreactivity and greater morphologic detail (Fig. 2) . At the resolution of the light microscope, IR-RSCP appears to be primarily cytoplasmic and absent from the nucleus. A prominent collection of arching fibers containing IR-RSCP (Fig. 3A) and IR-SS (Fig. 3B) emanate from the periventricular cells in a ventrolateral direction toward the optic chiasm and terminate in a dense band in the external zone of the median eminence (Fig. 4 A and B) , throughout its rostral caudal extent. Immunoreactive fibers also extend into the stalk and anterior portions of the posterior pituitary.
The cerebral cortex was also richly populated by neurons containing IR-RSCP, primarily in layers II, III, V, and VI (Fig.  5 (Fig. 4D) . In contrast, no immunoadis indicated within the pro-region. Numbering refers to sorption was apparent when antiserum previously adsorbed with )ositions within the precursor. excess synthetic SS-14 or synthetic SS-28 was used (Fig. 4C) .
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DISCUSSION
We have demonstrated that IR-RSCP is present in diverse regions of the central nervous system in both cell bodies and axon terminals in a distribution indistinguishable from that of IR-SS. The striking appearance of IR-RSCP in cell bodies of the hypothalamic periventricular system, their descending projections to the median eminence, and the presence of immunoreactive material within the terminals in the median eminence are compatible with the transport of IR-RSCP throughout the course of this neuronal system. Furthermore, the close proximity of immunoreactive material to the capillary plexus in the external zone of the median eminence makes it possible that this material is secreted into the portal vessels. Similarly, immunoreactive terminal fields in extrahypothalamic regions suggest that transport of the IR-RSCP from cell bodies of origin to axon terminals is a general phenomenon in the central nervous system and not limited exclusively to the hypothalamic tuberoinfundibular system.
Our findings on the somatostatin system bear many similarities to the neurohypophysial peptide system, in which posttranslational modification of propressophysin and prooxyphysin to vasopressin and oxytocin, respectively, occurs in secretory granules during axonal transport (26, 27) . By incorporating [3S]-cysteine into protein precursors synthesized in the supraoptic nucleus, Gainer et al (26, 27) have shown that the neurohypophysial prohormones are transported to the median eminence and posterior pituitary where the axon terminals are located (28 (31) and portal blood (32) .
The physiologic role of IR-RSCP in the central nervous system is unknown, but its presence in axons and axon terminals raises several possibilities. As found for neurophysin in the neurohypophysial system (33) , the IR-RSCP may have no specific endocrine activity but may serve as a carrier protein for and SS-28. In addition, as found for C-peptide in proinsulin (34) , the IR-RSCP may be secreted simultaneously with IR-SS and, if stable in body fluids, may serve as a marker for somatostatin secretion. Alternatively, the IR-RSCP may influence neurons directly or the anterior pituitary indirectly by way of the portal plexus and thereby act as a neuromodulator or hormone.
On the basis of the above data, we propose that, after biosynthesis in the neuronal perikarya, prosomatostatin is transported along the axon to nerve terminals during which time SS-14 and SS-28 are generated. Because IR-RSCP is present in axon terminals, this material may be secreted as a hormone or neuromodulator and may serve as a biologic marker of somato-
